The role of the canonical NF-kB pathway in mammary tumorigenesis was investigated using a transgenic (TG) mouse expressing a dominant-negative inhibitor of kB (IkBa SR (S32A/S36A) ) in the mammary gland under the control of the mouse mammary tumor virus promoter (MMTV). TG and control mice were subjected to a chemical carcinogenesis protocol. Hyperkeratinized squamous metaplasias (cytokeratinÀ6 þ /p63 þ ) sometimes with a basaloid island component, were found in both TG and control mice whereas luminal (cytokeratin-19 þ / MUC1 þ ) ErbB2 þ papillary and adenomatous lesions developed almost exclusively in control mice. p65/RelAand NF-kB DNA-binding activity were detected in mammary luminal lesions, but rarely in squamous metaplasias. Analysis of NF-kB family proteins and target genes using microarray data from a cohort of human mammary tumors revealed the expression of a canonical NF-kB pathway, but not non-canonical pathway proteins in HER2 þ luminal cancers. HER2 þ tumors also showed differential regulation of specific NF-kB target genes relative to basal and ER þ luminal cancers. Isolation of mammary cell populations enriched for stem and progenitor cell characteristics from an NF-kB-EGFP reporter mouse by fluorescence-activated cell sorting demonstrated that luminal progenitors contain activated NF-kB whereas the mammary stem cell-enriched population, does not. Together these data suggest that the canonical NF-kB pathway is active in normal luminal progenitor cells before transformation and is required for the formation of mammary luminal-type epithelial neoplasias.
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Introduction
The NF-kB family of proteins are a family of transcription factors which regulate a wide variety of genes and include c-Rel, RelB, RelA (p65), NF-kB1 and 2. Inhibitory members of the NF-kB family include IkBa, IkBb, IkBe and Bcl-3 which control nuclear localization and transcriptional activation (Hayden and Ghosh, 2004) . Activation is induced by the IkB kinases IKK-a, IKK-b. The predominate mechanism of regulation of NF-kB activity is through the canonical pathway through activation of IKK-b, as a result of inflammatory cytokine signaling, infectious agents and DNAdamage. IKK-b phosphorylates the inhibitor of kBa (IkBa) protein at serine residues 32 and 36 resulting in its ubiquitination, proteasome-mediated degradation and subsequent release of p65:p50 heterodimers for nuclear translocation (Karin, 1999) .
Multiple lines of evidence have suggested that NF-kB activity has an important role in both normal mammary development and breast cancer. Expression of a catalytically inactive mutant of IKKa in mouse mammary glands inhibits pregnancy-induced proliferation of mammary epithelium (Cao et al., 2001 ). An MMTV-IkBa SR transgenic mouse developed by the Sonenshein lab (Boston, MA, USA) (Demicco et al., 2005) demonstrated a delay in mammary gland differentiation which was resolved in conjunction with increased RelB/ p52 NF-kB activity. Thus NF-kB is essential for certain aspects of mammary gland differentiation although different NF-kB complexes may be active at different points in development. Breast cancer cell lines contain constitutive NF-kB activity. Higher levels of NF-kB activity correlate with increasing hormone independence (Nakshatri et al., 1997; Pratt et al., 2003) whereas a dominant-negative IKK-b reduces the tumorigenic potential of mouse mammary tumor cells (Biswas et al., 2001) . NF-kB activity is also induced by carcinogen in rat mammary glands and after malignant transformation of mammary epithelial cells (Kim et al., 2000) whereas c-Rel can induce mouse mammary tumors (Romieu-Mourez et al., 2003) . Diverse human breast cancers also have high levels of activated NF-kB (Cogswell et al., 2000; Zhou et al., 2005) . Inhibition of NF-kB with IkBa SR blocks the growth and causes regression of human mammary tumor cell xenografts in mice (Pratt et al., 2003) . Together these data suggest that NF-kB has a significant role in diverse processes in mammary development and cancer.
Mammary stem cells are functionally defined as cells that are able to regenerate whole glands after transplantation into cleared mammary fat pads. Progenitor or transit amplifying cells are usually committed to a specific lineage, which ultimately contributes to the structure and function of the mammary gland (Kordon and Smith, 1998; Dontu et al., 2003; Stingl et al., 2006) . Mammary stem and early progenitor cells are considered to be the likely targets for mutational propagation and subsequent transformation such that the features of cancer cells resemble the progenitors from which they are derived. Thus luminal cancer cells retain elements of luminal progenitors (Ince et al., 2007; Stingl and Caldas, 2007) .
Based on the involvement of NF-kB in both mammary differentiation and cancer we hypothesized that inhibition of NF-kB might prevent mammary tumor formation. Herein, we show that mammary expression of the IkBa SR is effective in preventing dimethyl-benzanthracene (DMBA)-induced premalignant and malignant mammary luminal-type epithelial lesions in mice.
Results

Generation and characterization of MMTV-IkBa
SR transgenic mice
To determine whether NF-kB activity is necessary for mammary tumorigenesis we developed a transgenic mouse expressing the stable repressor of NF-kB (IkBa SR ) in the mammary epithelium under the control of the MMTV-promoter. Five founder mice were obtained after microinjection of DNA into pronuclei of B6/C3F1-fertilized one-cell zygotes. Transgenic mice were identified by southern analysis of genomic tail DNA using a probe spanning the SV40 sequence. Founder lines were bred to wild-type mates to yield F1 animals and two were selected (lines 109 and 184) which displayed germ line transmission (Figure 1a) . Although it has been reported that MMTV-IkBa SR transgenic mice can present with lactation defects (Cao et al., 2001) others have found that early delays in ductal branching in pregnant IkBa SR mice are eventually resolved by activation of RelB/p52 signaling and the animals lactate normally (Romieu-Mourez et al., 2003) . Consistent with this our MMTV-IkBa SR transgenic females did not present with lactation difficulties. To confirm expression of the IkBa SR protein, mammary glands from 8-weekold MMTV-IkBa SR mice were excised and subjected to immunoblot analysis with an anti-FLAG monoclonal antibody. Figure 1b shows strong expression of the MMTV-IkBa SR FLAG protein in the mammary glands of mice from both founder lines whereas control wildtype (WT) mice did not contain anti-FLAG-reactive protein. Immunostaining of paraffin sections from mammary glands of 6-week-old TG and littermate WT mice for FLAG confirmed that the IkBa SR was expressed in the TG glands, in particular in the cytoplasm of the basal cell compartment. These sections also showed that ductal structures appeared normal compared with control mice (Figure 1c) . Whole mount analysis of TG mammary glands and littermate controls at 4 weeks of age demonstrated normal branching and end bud formation in both mice. Typical glands are shown in Figure 1d . Therefore, despite the presence of the canonical NF-kB inhibitor and consistent with the findings of Romieu-Mourez et al. (2003) , the presence of the IkBa SR transgene had no significant effect on either early development of the mammary gland or the ductal architecture.
MMTV-IkBa
SR mice are resistant to DMBA induction of premalignant and malignant mammary lesions The impact of inhibition of classical NF-kB activation on the induction of mammary tumorigenesis was examined by subjecting 21 female MMTV-IkBa SR mice (11 and 10 from each of the 109 and 184 founder lines, respectively) and 24 female WT mice to the MPA/ DMBA protocol. Animals were monitored for the formation of palpable masses after the final gavage as described in Materials and methods. Large variations in latencies for both groups of mice were observed, however, Kaplan-Meier analysis revealed that there was no significant difference between the appearance of palpable lesions between groups (Supplementary Figure  S1a) . Both founder lines showed a similar spectrum of latencies.
Control WT B6/C3F1 and MMTV-IkBa SR mice formed ventral masses ranging in location from cervical to inguinal. A table describing individual lesions can be accessed in (Supplementary Table S1 ). B6/C3F1 animals did not develop malignant tumors at a high rate after the DMBA protocol, but instead formed non-invasive adenomatous mammary lesions with high frequency. This protocol also produces a large number of basaloid lesions usually consisting of squamous metaplasia. Table 1 summarizes the pathological groups and frequencies. Histological examination of hematoxylin and eosin-stained WT lesions showed a total of 30 end point lesions in 22/24 mice wherein (43%) were reactive squamous lesions whereas 17 (57%) were mammary epithelial lesions. The majority of B6/C3F1 mammary lesions were histologically benign biphasic lesions with a papillary component in association with an adenoma component. Two fibroadenomas were also identified. In addition three invasive tumors were found as was a single incidence of ductal carcinoma in situ. In marked contrast, of 22 lesions detected in 18/21 MMTV-IkBa SR mice, 17 (77%) of these appeared as squamous lesions whereas only five (23%) were mammary epithelial hyperplastic masses. Four of the mammary lesions were benign papillary hyperplasias whereas one was a fibroadenoma. Figure 2 summarizes the percentages of each lesion type in both mouse groups and indicates that the proportion of squamous and mammary epithelial adenoma tumors in control animals was similar although the latter represented the majority of lesions. Conversely, these mammary adenomas represent the minority of lesions in the TG mouse because more than 75% of the lesions were squamous metaplasias. Survival analysis showed that although there was no difference between latencies in the two groups there was a trend toward a shorter latency in the TG mice (Supplementary Figure S1a) . We surmised that this might be indicative of differential pathologies and Kaplan-Meier analysis comparing mammary epithelial to squamous lesions showed a small but significant decrease in latency in the squamous tumors (Supplementary Figure S1b) . Thus, squamous lesions may develop more quickly than the mammary epithelial type lesions indicative of either higher proliferative rates and/or possibly divergent signaling pathways.
Hematoxylin and eosin-stained examples of sections from the most frequent pathological groups are shown in Figure 3a . In the top left panel, a poorly differentiated invasive carcinoma shows islands of tumor invading fibrotic stroma composed of cells with increased nuclear size, pleomorphism and mitotic activity. In the bottom left panel a biphasic papillary adenoma shows a circumscribed pushing border with the lesion made up of both a stromal spindle cell and a nested adenoma component. On the right side are regions of papillary hyperplasia. These were typically non-invasive lesions containing papillae made up of an epithelial surface with variable pleomorphism and cohesion surrounding a fibrovascular core. This type of lesion was found almost exclusively in WT mice (see Supplementary Table S1 ). In the right vertical panels, lesions from MMTV-IkBa a very mature extensively keratinized lesion (bottom right). In some lesions hair follicles had formed consistent with trichogenic squamous differentiation (not shown). Thus DMBA induction results in a heterogeneous array of mammary epithelial lesions as well as squamous metaplasias with and without basaloid components.
To further characterize the two main lesion types we stained both mammary epithelial and squamous sections for several basal and luminal markers. Figure 3b upper panel depicts typical immunostaining of a squamous lesion for the basal cytokeratin, CK6 which is a marker of stem and basaloid progenitor cells and the basal cell marker, p63 which is present in both squamous and sarcomatoid metaplasias (Tse et al., 2006) . Cells constituting the basaloid islands within squamous metaplasias contained both CK6 (shown) and p63-positive cells (not shown) as did areas of squamous differentiation with extensive keratinization shown immunostained for p63. These basal cells surround the areas of keratinization, consistent with the possibility that keratin has been deposited into the lumen of the former duct.
Next, we immunostained mammary adenomatous lesions with both basal and luminal protein antibodies. Figure 3c shows representative images of a typical biphasic tumor with a papillary component (P) shown to the left of the demarcation line in all panels, and an adenoma component (A) on the right. The papillary structures consist of a network of ductal-like structures circumscribed by a basal cell component positive for the basal cell markers, smooth muscle actin (sma) and p63. These cells are interspersed with or surround an area of disorganized hyperproliferative luminal cells, which do not stain with the basal markers. All of the papillary regions are positive for the luminal markers CK19 (CK18 in Supplementary Figure S2 ) and MUC1. Most of the papillary lesions undergo transition to an adenoma phase, which is devoid of basal cell markers but expresses the luminal cell markers.
Therefore, our results demonstrate that IkBa SR expression significantly and specifically inhibits the formation of mammary luminal neoplasias but does not prevent the formation of basally derived, differentiated squamous lesions
NF-kB activation and p65 expression in mammary lesions
Based on the preferential impact of the inhibition of NF-kB on mammary epithelial lesions, we hypothesized that NF-kB would be present in mammary epithelial lesions but not in squamous lesions. To assess NF-kB activation in the different lesion types we performed an electrophoretic mobility shift assay (EMSA) using an NF-kB consensus sequence on nuclear extracts from representative lesions from both wild-type and TG mice (Figure 4a ). Mammary adenomas and a tumor derived from control mice displayed constitutive NF-kB activity whereas squamous lesions did not. Two of four mammary lesions from MMTV-IkBa SR mice (two are shown) showed clear evidence of NF-kB activation.
These findings could be the result of either insufficient transgene expression or activation of NF-kB through an IkBa-independent pathway. The numerous squamous lesions were devoid of NF-kB DNA-binding activity. Normal mammary gland from a control mouse showed no evidence of NF-kB activation. EMSA of the Sp1 probe was used as a relative loading control for the tumor nuclear extracts.
We next immunostained sections from different lesion types from both control and MMTV-IkBa SR mice to assess p65 localization. Figure 4b demonstrates that staining for p65 was frequently nuclear in cells within mammary adenomatous lesions from both groups of mice exemplified by the upper panel. In contrast to the mammary epithelial lesions, those with squamous differentiation showed lower expression of p65 and no evidence of nuclear localization.
Relative expression of p65/RelA in protein extracts from different lesions in both mice were also assessed by immunoblot. Figures 5a-c demonstrates clearly that a high relative level of p65 expression was generally associated with mammary lesions. With the exception of two squamous lesions, p65/RelA was present at very low levels in the squamous lesions. No differences were observed between TG and WT mice. Panel D shows that p65/RelA expression is elevated in malignant (M(T)) and an adenoma-type luminal lesion relative to B6/ C3F1 WT normal mammary gland.
Using an antibody against phospho-IKK-a/IKK-b we found that IKK-b but not IKK-a was phosphorylated in nearly all mammary biphasic lesions in control and MMTV-IkBa SR mice, respectively, but is only weakly expressed and not phosphorylated in squamous lesions (Figures 5e and f) . Normal mammary tissue contained nearly undetectable phosphorylated IKK-b relative to the lesions (Figure 5g) . Figure 5h is a control showing phosphorylated IKK-a and -b in TNF-treated MCF-7 cell extracts. Thus the IKK-b subunit is the major IkB kinase activated in DMBA-induced noninvasive and malignant adenomatous mammary tumors.
Pilar or trichogenic squamous cell tumors often demonstrate high levels of apoptosis in conjunction with the formation of the outer root sheath during early categen (Ackerman et al., 1993) . Because of the extensive squamous differentiation and evidence of aborted hair follicles, we evaluated apoptosis in all of the lesions. Cleavage of poly ADP-ribose polymerase (PARP) by caspase-3 is indicative of apoptosis (Soldani and Scovassi, 2002) . The results in Figure 5a -c (second and third panels) indicate that PARP cleavage was widely observed in samples of squamous lesions and seldom in mammary adenomas. As predicted by the PARP cleavage, the squamous lesions contained large numbers of apoptotic cells compared with a biphasic mammary tumor (Supplementary Figure S3) . Thus, DMBA-induced squamous metaplasias show evidence of differentiation and develop in the absence of NF-kB activity.
Mammary epithelial lesions induced by DMBA express ErbB2
A subset of luminal-type tumors express high levels of the ErbB2 protein (Stingl and Caldas, 2007) . The EGFreceptor family has been implicated in NF-kB activation (Habib et al., 2001; Pianetti et al., 2001; Chen et al., 2003) . To assess ErbB2 expression relative to normal mammary gland in DMBA-induced premalignant mammary and squamous lesions we performed immunoblot analysis. Typical results are shown in Figure 6 indicating that ErbB2 is highly expressed in nearly all of the mouse mammary lesions (M) regardless of malignant status, and could, therefore, contribute to the mechanism of sustained or increased activation of NF-kB in DMBA-induced tumors. In contrast, ErbB2 was expressed at very low levels in basaloid/squamous (S) lesions. Together these data suggest that ErbB2-positive luminal mammary neoplasias contain activated NF-kB and that inhibition of the canonical NF-kB pathway is sufficient to strongly inhibit the formation of these lesions.
The canonical NF-kB pathway constituents prevail in human HER2 þ luminal cancers As inhibition of the canonical NF-kB pathway prevented DMBA-induced luminal neoplasias, we next wanted to determine if there are differences between the estrogen receptor-positive and HER2/neu-positive luminal subtypes of human tumors with respect to NF-kB targets and NF-kB. In addition, we wished to compare these groups to basal tumors. To accomplish this a collection of tumors probed on Affymetrix platform U133A,B from the Karolinska Institute, Stockholm, Sweden (Uppsala set, GEO: GSE4922) (Calza et al., 2006) was used. These tumors had been classified as ERÀ/HER2À, HER2 þ (majority are ERÀ) and ER þ / HER2À, according to a recent meta-analysis carried by Wirapati et al. (2008) . We used MAS 5.0 calls for the probe sets as present/absent/marginal. Of 104 NF-kB target genes assessed, a subset is expressed in breast cancers. Table 2 shows some of these genes and indicates the percentage of tumors in which the protein was present in each group. Several genes were differentially present in both HER2 þ and basal-type tumors relative to ER þ tumors. Two of these are directly related to immune cell signaling, including CXCL5 and defensinB1 consistent with an inflammatory signaling component in these types of tumors. The cancer stem cell marker CD29 is also more prominently associated with basal and HER2 þ cancers. The antiapoptotic protein A1 was also frequently present in the latter tumor types. Interestingly, the pentaxin-related gene induced by interleukin-1 was differentially regulated in the HER2 þ cancers suggesting that NF-kB-induced genes may contribute to the gene signatures of subtypes of breast cancer. Differential expression of interleukin-1 isoforms was evident in the three types of tumors, which may signify different immune responses to these cancers.
We also examined the percentage of each group of cancers expressing various members of the NF-kB pathway. Most of these proteins are expressed with a similar frequency within each group. However, a strong segregation of the HER2 þ and ER þ tumors relative to basal tumors with respect to RelB and NF-kB2 expression is clearly evident. On the other hand, HER2 þ and ER þ tumors demonstrate a similar propensity to express the canonical NF-kB pathway protein, NF-kB1. Thus, although HER2 þ cancers share some NF-kB-inducible genes with basal breast cancers, they have an NF-kB protein profile indicative of the canonical pathway and similar to ER þ luminal cancers.
Mammary stem and progenitor cell-enriched populations contain differentially activated NF-kB Mammary stem-like basally located cells are termed mammary repopulating units (MRUs) as they are able to regenerate the mammary gland in mice. A population of luminal progenitor cells can also be isolated from the mammary gland termed mammary colony-forming cells (Ma-CFCs) (Stingl et al., 2006) . As NF-kB was activated in ErbB2-expressing mammary neoplastic cells and formation of these lesions was reduced by inhibition of NF-kB, we sought to determine whether or not the luminal progenitor population contains activated NF-kB. Using mammary glands from transgenic mice harboring a 3X cis-NF-kB-EGFP reporter gene, we sorted CD49f Figure 7h . To correlate previously described culture characteristics of MRU and Ma-CFC-enriched populations with our cell sorting parameters, we assayed the growth characteristics of sorted populations in a 3-dimensional culture system. Figure 7i shows that the CD49f high /CD24 low population shown in the literature to be associated with MRU activity and shown here to contain almost no EGFP þ cells formed both round and amorphous colonies in Matrigel whereas the Ma-CFC-enriched CD49f low /CD24 high population containing a high proportion of EGFP þ cells produced branching acinar structures (not shown) in which one or two layers of epithelial cells surround a lumen similar to the formations described by Stingl et al. (2006) . (Figure 8 ) These results suggest that NF-kB is activated during the normal course of differentiation in the Ma-CFC/ luminal progenitor but not the stem cell-enriched populations.
Discussion
The marked reduction of DMBA-mediated induction of mammary luminal neoplastic lesions and cancers in MMTV-IkBa SR mice suggests that NF-kB inhibition prevents one or more essential steps early in tumorigenesis in this compartment. The lack of p65 protein and NF-kB activation in squamous lesions provides a likely explanation for why the development of these lesions is relatively unaffected in mice carrying the IkBa SR transgene, despite the fact that the MMTV-promoter is active in both luminal and basal mammary epithelium (Wagner et al., 2001) . Virtually all DMBA-induced mammary luminal lesions expressed high levels of ErbB2 in comparison to both normal mammary gland and squamous lesions thereby resembling human HER2/neu þ breast cancer. EGF-receptor family members activate NF-kB through Akt and CK2 (Pianetti et al., 2001) or NF-kB-inducing kinase-mediated me- Figure 7 Fluorescence-activated cell sorting analysis of populations previously shown to be enriched with stem and progenitor cells. Cis-NF-kB-EGFP normal mammary glands were isolated as described in Materials and methods. Mouse mammary cells were labeled with anti-CD24PE and anti-CD49fAPC and subjected to FACS analysis. Population distributions were calculated according to Stingl et al. (2006) . ( chanisms (Habib et al., 2001; Chen et al., 2003) . This is consistent with nearly perfect correlation between ErbB2 expression and NF-kB-containing mammary lesions in the DMBA model. Thus, it is tempting to assume that NF-kB activity in luminal cancers is a function of ErbB2 activity. However the presence of activated NF-kB in a large majority of normal mammary luminal progenitor cells suggests that NF-kB is already active during the normal course of mammary gland differentiation in this population. Apart from the relatively large numbers of luminal progenitor cells in the gland, this intrinsic NF-kB activity may render this population more susceptible to transformation and carcinogenesis. Interestingly, although the most common type of luminal breast cancers are the hormone-dependent estrogen receptor (ER) þ group which appear to have little NF-kB activity, this activity is reactivated in the absence of E2 (Pratt et al., 2003) . This suggests that NF-kB is tonically activated in this subset of luminal progenitors/tumors but is repressed by the ER. Basal breast cancer cell lines express activated NF-kB (Biswas et al., 2001; Singh et al., 2007) . However, given that the putative mammary stem cell population was negative for GFP and p65/ RelA, it is likely that NF-kB becomes activated as a consequence of transformation in basal progenitors.
Analysis of human breast cancer microarray data for NF-kB-regulated genes and genes for NF-kB proteins showed that HER2 þ breast cancers share gene expression patterns with both basal and luminal cancers. Although the presence of immune regulatory molecules and targets were similar between basal and HER2 þ breast tumors, both HER2 þ and ER þ luminal cancers showed a strong tendency to exclusively express proteins involved in the canonical NF-kB family. This is in contrast to basal tumors in which a large percentage of tumors express RelB, a constituent of the non-canonical pathway, a finding similar to that of Wang et al. (2007) . Together with our TG mouse experiments, these gene expression data support the notion that the canonical NF-kB pathway has a significant role in ErbB2 þ luminal cancers.
MMTV-Wnt1 and MMTV-stable DNb-catenin transgenic mice develop multiple lobuloalveolar hyperplasias, a subset of which progresses to focal carcinomas and many pilar squamous (hair follicle-containing tumors) forms (Miyoshi et al., 2001 induced squamous metaplasias were not invasive and strongly expressed the basal cytokeratin CK6 but not ErbB2, features which were recently described in human squamous carcinoma of the breast (Grenier et al., 2007) . They also contained cells positive for the basal cell and metaplasia marker, p63. Thus, inhibition of the canonical NF-kB pathway does not prevent DMBA-induced basaloid squamous metaplastic lesions.
Further studies in models of basal mammary cancers will be necessary to determine whether the various forms of malignant basal tumors require this transcription factor. In a separate study, Cao et al. (2007) showed that mice expressing mutant IKK-a to target the noncanonical NF-kB pathway, develop DMBA mammary lesions with long latency and significantly more lesions were squamous metaplasias relative to controls. This may indicate a role for the non-canonical pathway in luminal tumorigenesis in this model and/or the ablation of other functions of the IKK-a protein including repression of the FOXO3a tumor suppressor (Hu et al., 2004) or silencing of p53-induced transcription (Huang et al., 2007) .
Combining our current findings with our previous work and data in the literature we propose a model in which NF-kB activity is present in luminal progenitor cells, which are candidate targets of transformation in the mammary gland (Figure 8 ). The luminal progenitor population can give rise to two types of committed progenitors that have active NF-kB, which appears to be due to activation of the canonical pathway. Alveolar progenitors are thought to express ErbB2, whereas a second lineage encompasses the hormone-responsive ER þ cells (Stingl and Caldas, 2007) . ErbB2 can further activate while the ER will repress NF-kB. The present work shows that DMBA promotes tumorigenesis in the ErbB2 þ /NF-kB-activated population. Together these data provide a mechanism whereby inhibition of NF-kB has an inhibitory effect on the genesis of these tumors.
Materials and methods
Mice
Generation of MMTV-IkBa SR transgenic mice. The mouse mammary tumor virus promoter construct (MMTV-SV40-BSSK) (Guy et al., 1992) was obtained from Dr W Muller (McGill University, Montreal) and is active in the mammary glands of mice at sexual maturity and without requirement for pregnancy or lactation. Briefly, we have cloned the Flag-tagged S32/36A IkBa SR cDNA (Iimuro et al., 1998) (obtained from Dr A Baldwin, University of North Carolina, Chapel Hill, NC, USA) into the MMTV-SV40-BSSK plasmid. Five founder mice were obtained after microinjection of linearized DNA into pronuclei of B6/C3 fertilized one-cell zygotes. Transgenic mice were identified by southern analysis of tail DNA using a probe spanning the SV 40 sequence. Expression of the transgene was confirmed by immunblot for Flag-IkBa SR as well as immunohistochemistry with rabbit anti-Flag and horseradish peroxidase secondary antibody on paraffin sections of mammary glands from 5-week-old mice.
C57/BL6 3X cis-NF-kB-EGFP transgenic mice. This mouse carries three copies of the HIV NF-kB response element upstream of the minimal c-fos promoter driving EGFP and was the generous gift of Dr C Jobin (Magness et al., 2004) .
Microarray analysis
We analysed the breast tumor microarray collection from the Karolinska Institute (Uppsala set, GEO: GSE4922) (Calza et al., 2006) . This set consists of 249 tumors probed on the Affymetrix platform U133A,B. Tumors were classified as ERÀ/HER2À, HER2 þ and ER þ /HER2À, according to a recent meta-analysis carried by Wirapati et al. (2008) . This cohort contained 14.3% basal-like, 10.4% ERBB2 þ , 42.7% luminal A/B, 22.1% normal-like and 10.4% unclassified tumors (Calza et al., 2006) . We used MAS 5.0 (Microarray Analysis Suite, Affymetrix, Santa Clara, CA, USA) calls for the probe sets as present/absent/marginal. A present call for a probe set indicates that the corresponding gene is expressed in the tumor. NF-kB targets (104 genes) were extracted from Dr Gilmore's website http://people.bu.edu/gilmore/nf-kb/target/ index.html, and mapped to 197 array probe sets through NetAffx.
Preparation of surface antigen-defined mammary stem and progenitor cell-enriched populations and fluorescence-activated cell sorting For each of the three experiments four inguinal mammary glands from 2, 9-week-old TG-NF-kB mice were isolated and subjected to digestion for 8 h at 371C using Epi-Cult-B with 5% FBS, collagenase and hyaluronidase as described (Stingl et al., 2006 ) using a reagent kit from StemCell Technologies Inc. (Vancouver, BC, Canada). All manipulations were performed essentially according to the manufacturer's instructions and details are presented in Supplementary Information.
Three-dimensional extracellular matrix assay FACS-sorted mammary MRU and Ma-CFC cells were placed in Matrigel and cultured in Epi-Cult-B medium (StemCell Technologies) in the presence of cytokines and 5% FBS with frequent medium changes as described (www.stemcell.com). Cultures were terminated after 14 days, Matrigel plugs were paraffin-embedded, sectioned and then stained with hematoxylin and eosin.
Immunoblots and antibodies
Frozen tumor samples were pulverized under liquid N2.
Samples were processed as whole tumor extracts for immunoblot analysis as previously described (5). 
